dihexa clinical trials trial humans human dihexa human clinical 2026 dihexa human trials status 2026 SCOPE 2026, Simplified Patient Recruitment Management, AI Powered Clinical Trial Finders and More… – TrialX dihexa human dihexa clinical trials humans BPC

Increases in resting heart rate are a recognised class effect of incretin-based therapies and have been reported with GLP-1 receptor agonists more broadly, as reflected in the Summary of Product Characteristics (SmPC) for licensed agents such as semaglutide (Wegovy) and liraglutide (Saxenda)

Previous studies have reported inconsistent results when comparing oral, sublingual, and intramuscular administration, often limited by small sample sizes or heterogeneous populations (Houle et al., 2014

PMID 11109517

Osteoporosis Osteoporosis is a condition of reduced bone density

These mixed signals underscore how little we truly know about BPC-157s influence on cancer pathways